LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer

  • Sas‐Chen A
  • Aure M
  • et al.
78Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

Abstract

Long noncoding RNA s (lnc RNA s) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lnc RNA s have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal‐like subtype associates with increased EGFR signaling, while another, the HER 2‐enriched subtype, engages a kin of EGFR . Based on the premise that EGFR ‐regulated lnc RNA s might control the aggressiveness of basal‐like tumors, we identified multiple EGFR ‐inducible lnc RNA s in basal‐like normal cells and overlaid them with the transcriptomes of over 3,000 breast cancer patients. This led to the identification of 11 prognostic lnc RNA s. Functional analyses of this group uncovered LINC 01089 (here renamed Lnc RNA Inhibiting Metastasis; LIMT ), a highly conserved lnc RNA , which is depleted in basal‐like and in HER 2‐positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo . In conclusion, lnc RNA s dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers. image A long noncoding RNA , named LIMT , is downregulated by growth factors and accordingly expressed at low level in aggressive subtypes of breast cancer. LIMT inhibits metastasis in animals, possibly by reducing motility of cancer cell migration. EGF dynamically regulates the expression of lncRNAs. Expression of several EGF ‐regulated lnc RNA s correlates with clinical outcome of breast cancer patients. LIMT is an EGF downregulated lnc RNA , which inhibits cell migration in vitro and metastasis in vivo . Aggressive, growth factor‐driven subtypes of breast cancer express relatively low levels of LIMT .

Cite

CITATION STYLE

APA

Sas‐Chen, A., Aure, M. R., Leibovich, L., Carvalho, S., Enuka, Y., … Yarden, Y. (2016). LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Molecular Medicine, 8(9), 1052–1064. https://doi.org/10.15252/emmm.201606198

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free